Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
EU panel approves drug for rare genetic disease
Blood, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), Familial Chylomicronemia Syndrome (FCS), Fat Accumulation, FDA, FDA/Regulatory, Inflammation, Pancreas, Platelet Count, Rare Genetic Diseases, Recommended For ApprovalAn advisory committee of the EMA recommended conditionally approving a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a rare genetic disease.